News from atai life sciences A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 07, 2021, 08:45 ET atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders

atai Life Sciences ("atai" or the "Company"), a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various...

Apr 06, 2021, 09:31 ET Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia

Recognify Life Sciences, Inc. (Recognify), an atai Life Sciences (atai) platform company focused on developing treatments for cognitive impairment...

Mar 16, 2021, 05:00 ET Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders

Perception Neuroscience (Perception), an atai Life Sciences (atai) company focused on developing innovative therapies in neuropsychiatric disorders,...

Mar 10, 2021, 08:00 ET DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder...

Mar 03, 2021, 08:00 ET atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

atai Life Sciences ("atai" or the "Company"), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for...

Feb 19, 2021, 08:00 ET Perception Neuroscience's PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study

Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in...

Jan 26, 2021, 08:00 ET atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents

atai Life Sciences ("atai" or the "Company"), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health ...

Jan 12, 2021, 08:00 ET atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment Associated with Schizophrenia

atai Life Sciences ("atai" or the "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...

Dec 16, 2020, 11:44 ET atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer

atai Life Sciences ("atai" or the "Company"), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health ...

Nov 23, 2020, 11:00 ET ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round

ATAI Life Sciences ("ATAI" or the "Company"), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health ...

Oct 27, 2020, 08:30 ET ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

ATAI Life Sciences ("ATAI" or the "Company"), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental...

Aug 24, 2020, 09:00 ET ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product

Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for various mental health...

Aug 20, 2020, 09:30 ET ATAI and IntelGenx enter into Feasibility Agreement to develop pharmaceutical-grade polymeric film technologies for delivery of psychedelic medicines

Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental...

Jul 22, 2020, 10:00 ET ATAI launches Viridia Life Sciences to develop novel formulations of N, N-Dimethyltryptamine (DMT) for a range of mental health conditions

Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental...

Jul 22, 2020, 07:00 ET ATAI Life Sciences to Host Virtual R&D Day on July 29, 2020

ATAI Life Sciences AG, a global biotechnology company builder that envisions an end to mental illnesses, today announced that it will host a virtual...

Jul 09, 2020, 12:30 ET ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse

ATAI Life Sciences AG, a global biotechnology company builder that envisions an end to mental illnesses, has acquired a majority stake in New...

Jun 22, 2020, 10:00 ET ATAI launches IntroSpect Digital Therapeutics, appoints veteran software engineer David Keene as CEO

Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for various mental health...

Jan 24, 2020, 09:30 ET ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

ATAI Life Sciences AG ("ATAI" or the "Company"), a global biotech platform that envisions an end to mental illnesses, today announced an investment...

Jan 06, 2020, 09:00 ET ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)

ATAI Life Sciences AG ("ATAI" or the "Company"), a global biotech platform that envisions an end to mental illnesses, today announced that it has...

Sep 20, 2019, 09:00 ET GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder...